NCT06328777 - RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 2, 2024

Primary Completion Date

July 31, 2029

Study Completion Date

July 31, 2029

Conditions

Systemic SclerosisScleroderma

Interventions

BIOLOGICAL

CABA-201

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Trial Locations (10)

RECRUITING

Columbia University Irving Medical Center, New York

RECRUITING

University of Rochester, Rochester

RECRUITING

Duke University, Durham

RECRUITING

University of Michigan, Ann Arbor

RECRUITING

Mayo Clinic Florida, Jacksonville

RECRUITING

Mayo Clinic Rochester, Rochester

RECRUITING

Northwestern Memorial Hospital, Chicago

RECRUITING

The University of Chicago Medical Center, Chicago

RECRUITING

University of Kansas Medical Center, Kansas City

RECRUITING

Yale University, New Haven